SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Min  Hr  Day  Wk  Mon  Yr  3 Yr  Log
Introduction Market Data Compact
REGN 654.06+0.2%Oct 30 3:59 PM EDT
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3557George presentation Love the pipeline but it looks like it will be a rough yeaBioBait-April 29
3556Update. Total Eylea is down again First quarter 2025 revenues of $3.0 billion;A.J. Mullen-April 29
3555Guessing that the lower selling price higher volume of 2mg impacted the conversaBioBait-11/1/2024
3554Thoughts on poor Eylea HD sales?Felix B-10/31/2024
3553Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea inveA.J. Mullen-9/25/2024
3552Nice, Regeneron paid out the first cash bonus for Decibel milestone of treating BioBait-8/19/2024
3551Hmmm interesting, they must be confidence in the C5 program and others to back iFelix B-8/15/2024
3550Alnylam partnership Updated collaboration agreements with Regeneron.Amended licBioBait-8/1/2024
3549Dupi 3.3b page 6BioBait17/31/2024
3548Aln-ang3 Another trial that regeneron is runningBiotechwantabe-6/12/2024
3547Dupi 20B in 2026? Seem a bit optimistic to do 20% penetration by 2026.Biotechwantabe-6/12/2024
3546From math stand points, 25% now is > than 30% 12 months early. However, from Miljenko Zuanic-4/29/2024
3545Q1 presentation Check out slides6-8. Slowing growth from 30 to 25%. Not Biotechwantabe-4/26/2024
3544Dupi okay? reuters.comFelix B-4/25/2024
3543When you got $B in the bank, taking a few shots on goal is not bad. Alnylam iBiotechwantabe14/25/2024
3542I think that ALNY opted out for those two candidates, and probably for few more!Miljenko Zuanic-4/24/2024
3541I would not read too much into their omission. Same omission in classic.clinicaBiotechwantabe-4/24/2024
3540And ALNY was not at all mentioned in trial protocol??? ....hmmmm... It is not paMiljenko Zuanic-4/24/2024
3539A Trial to Learn if REGV131-LNP1265 is Safe and Works to Help the Body Make ClotBiotechwantabe-4/23/2024
3538Another Alnylam partnered program First in Human (FIH) Study of ALN-SOD in AdulBiotechwantabe-4/8/2024
3537Another obesity patent. Treatment of obesity in subjects having variant nucleicBiotechwantabe-3/26/2024
3536CRL Regeneron's blood cancer therapy faces setback as FDA raises trial conceBiotechwantabe-3/25/2024
3535There is is another company testing a similar approach which should have full stFelix B13/22/2024
3534Some patent links: freepatentsonline.com freepatentsonline.comBiotechwantabe-3/12/2024
3533Interesting. I've seen data showing rats lose a lot of muscle, along with faA.J. Mullen-3/12/2024
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News